Yasuko Rikihisa
Immunology and Microbiology · The Ohio State University
Publications
344
Citations
26,751
Est. group size
~8
Recurring co-author estimate
Active years
51
Publishing since 1976
Yasuko Rikihisa studies tick-transmitted bacterial pathogens, particularly Ehrlichia, Anaplasma, and Neorickettsia species that cause diseases in humans, dogs, and horses. Her work investigates how these bacteria invade and manipulate host cells at the molecular level, and applies these insights toward developing vaccines and treatments, including newer mRNA-lipid nanoparticle vaccine approaches. This research combines molecular microbiology, cell biology, and immunology to address vector-borne infectious diseases of veterinary and public health importance.
Publication output has been variable but sustained over the last decade, with recent years (2024-2026) showing a notable increase in output after a dip in 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Efficacy and immunological correlates of an mRNA-LNP vaccine for protection against an emerging rickettsial pathogen
Emerging Microbes & Infections · 2026
- <i>Anaplasma phagocytophilum</i> Subversion of Host Hepcidin-Ferroportin Iron Nutritional Immunity
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Equine neorickettsiosis: A global perspective of the natural habitat of the bacteria and clinical disease
Veterinary Microbiology · 2026
- Efficacy and immunological correlates of an mRNA-LNP vaccine for protection against an emerging rickettsial pathogen
Figshare · 2026
- Efficacy and immunological correlates of an mRNA-LNP vaccine for protection against an emerging rickettsial pathogen
Figshare · 2026
- <i>Anaplasma phagocytophilum</i> subversion of host hepcidin-ferroportin iron nutritional immunity
mBio · 2026
- Obligatory intracellular bacterium Anaplasma phagocytophilum AnkA regulates actin dynamics and spatiotemporal bacterial release
PLoS Pathogens · 2026
- Development of mRNA–lipid nanoparticle intrabodies against rickettsial infection
Journal of Biomedical Science · 2025
- <i>Anaplasma phagocytophilum</i> effector EgeA facilitates infection by hijacking TANGO1 and SCFD1 from ER–Golgi exit sites to pathogen-occupied inclusions
Proceedings of the National Academy of Sciences · 2024
- RipE expression correlates with high ATP levels in Ehrlichia, which confers resistance during the extracellular stage to facilitate a new cycle of infection
Frontiers in Cellular and Infection Microbiology · 2024
- Development of Etf-3-specific nanobodies to prevent Ehrlichia infection and LNP-mRNA delivery in cellular and murine models
Microbiological Research · 2024
- Analysis of Amblyomma americanum microRNAs in response to Ehrlichia chaffeensis infection and their potential role in vectorial capacity
Frontiers in Cellular and Infection Microbiology · 2024
- Analysis of <i>Amblyomma americanum</i> microRNAs in response to <i>Ehrlichia chaff</i> eensis infection and their potential role in vectorial capacity
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Inhibition of <i>Ehrlichia chaffeensis</i> infection by cell-permeable macrocyclic peptides that bind type IV secretion effector Etf-1
PNAS Nexus · 2023
- Diagnosis of Potomac horse fever (syn. equine neorickettsiosis) in 2 foals in southwestern Ontario.
PubMed · 2023
- mBio×10
- Proceedings of the National Academy of Sciences×5
- Frontiers in Cellular and Infection Microbiology×5
- Figshare×4
- Autophagy×3
- Mingqun Lin
Immunology and Microbiology · The Ohio State University
- Nan Duan
Immunology and Microbiology · The Ohio State University
- Risa Pesapane
Immunology and Microbiology · The Ohio State University
- Alexander Welker Biondo
Immunology and Microbiology · Purdue University West Lafayette
- Oghenekaro Omodior
Immunology and Microbiology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile